Key references: Management of diabetic kidney disease
American Diabetes Association. 9. Cardiovascular disease and risk management: Standards of medical care in diabetes-2018. Diabetes Care 2018;41(Suppl 1):S86–S104. https://www.ncbi.nlm.nih.gov/pubmed/29222380
American Diabetes Association.10. Microvascular complications and foot care: Standards of medical care in diabetes-2018. Diabetes Care 2018;41(Suppl 1):S105–S18. https://www.ncbi.nlm.nih.gov/pubmed/29222381
Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375(9721):1173–81. https://www.ncbi.nlm.nih.gov/pubmed/20170948
Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Alan C, et al. National evidence based guideline for diagnosis, prevention and management of chronic kidney disease in type 2 diabetes. Canberra: Diabetes Australia and NHMRC; 2009. https://www.nhmrc.gov.au/guidelines/publications/di18
Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, et al. The CARI guidelines. Prevention and management of chronic kidney disease in type 2 diabetes. Nephrology (Carlton) 2010;15 Suppl 1:S162–94. https://www.ncbi.nlm.nih.gov/pubmed/20591029
Craig ME, Twigg SM, Donaghue K, Cheung NW, Cameron FJ. National evidence-based clinical care guidelines for type 1 diabetes for children, adolescents and adults. Canberra: Australian Department of Health and Ageing; 2011. www.diabetessociety.com.au/position-statements.asp
Diabetes Canada Clinical Practice Guidelines Expert Committee. McFarlane P, Cherney D, Gilbert RE, Senior P. Chronic kidney disease in diabetes. Can J Diabetes 2018;42 Suppl 1:S201–S9. https://www.ncbi.nlm.nih.gov/pubmed/29650098
Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 2017;54(10):933-41. https://www.ncbi.nlm.nih.gov/pubmed/28748377
Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383(15):1436-46. https://www.ncbi.nlm.nih.gov/pubmed/32970396
Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359(23):2417–28. https://www.ncbi.nlm.nih.gov/pubmed/19052124
Jun M, Ohkuma T, Zoungas S, Colagiuri S, Mancia G, Marre M, et al. Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results from ADVANCE-ON. Diabetes Care 2018;41(1):163–70. https://www.ncbi.nlm.nih.gov/pubmed/29079715
Newman CB, Blaha MJ, Boord JB, Cariou B, Chait A, Fein HG, et al. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2020;105(12). https://www.ncbi.nlm.nih.gov/pubmed/32951056
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020;383(15):1413-24. https://www.ncbi.nlm.nih.gov/pubmed/32865377
Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6(8):605-17. https://www.ncbi.nlm.nih.gov/pubmed/29910024
Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, et al. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol 2018;29(11):2755-69. https://www.ncbi.nlm.nih.gov/pubmed/30314978
